Ropca ApSAktiv

ROPCA develops, produces, and markets an AI and robotics-based automation platform for ultrasound examinations. Our initial market focus is Rheumatology, where our products offer a solution that relieves clinical workload, reduces costs, and ensures faster and more consistent diagnostics—without requiring a specialist to be present.

Financial PerformanceThe income statement for 2025 records a net loss of DKK 5,159,653, compared to a loss of DKK 2,313,445 in the prior year. The balance sheet as at 31 December 2025 reflects total equity of DKK 13,580,552. To support continued development and commercialisation activities, the Company completed a capital increase of DKK 4,756,385 during the year, strengthening the equity base and providing additional working capital for ongoing operations.Commercial and Clinical Progress2025 represented another year of meaningful advancement for ROPCA across both commercial and clinical dimensions. The Company completed five new ARTHUR installations during the year, further expanding its installed base across Denmark, Germany, Austria, Switzerland, and the United States, where ARTHUR is now operational at Mayo Clinic. These additions reinforce ARTHUR's position as the leading automated ultrasound solution in rheumatology. Cumulatively, ARTHUR has now performed more than 4,600 scans covering in excess of 62,000 joints across the installed base. Commercial momentum continues to be underpinned by strong clinical endorsement from leading institutions. Clinicians at University Hospital Svendborg in Denmark and University Hospital Düsseldorf in Germany have highlighted ARTHUR's contribution to patient prioritisation, examination throughput, and consistency of diagnostic quality.Product DevelopmentIn parallel with its commercial activities, ROPCA continued the development of UNA, t

Uddrag af ledelsesberetningen i den seneste årsrapport.